AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026110129
Submit to EJMO
Cite this article
5
Download
22
Views
Related Info Links
Google Scholar
More by Authors Links
Jin Hu
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Prognostic evaluation and immune microenvironment profiling of Ewing sarcoma through characterization of lipid metabolism-related genes

Kailuo Xie1 ,  Wenbin Liu1 ,  Jin Hu1*
Show Less
1 Department of Orthopedics, Wenzhou People’s Hospital, Wenzhou, Zhejiang, China
EJMO, 026110129 https://doi.org/10.36922/EJMO026110129
Received: 14 March 2026 | Revised: 15 May 2026 | Accepted: 4 June 2026 | Published online: 6 July 2026
(This article belongs to the Special Issue Tumor Immune Microenvironment and Intervention Strategies)
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Introduction: Lipid metabolism contributes to tumor progression and immune regulation in Ewing sarcoma (EwS), but its relationship with prognosis and tumor immune microenvironment (TIME) remains inadequately clarified.

Objectives: This study investigated lipid metabolism-related gene (LMRG) subtypes, their associations with immune microenvironmental characteristics, and the prognostic value of an LMRG-based risk model in EwS.

Methods: Transcriptomic datasets of EwS from GEO (GSE17679; training cohort) and ICGC (validation cohort) were analyzed using computational techniques. LMRG subtypes were identified by consensus clustering. The TIME was inferred using ESTIMATE, TIMER algorithm, and single-sample gene set enrichment analysis (ssGSEA). A multigene risk score model was developed through LASSO and multivariable Cox regression, evaluated with Kaplan–Meier survival curves and time-dependent receiver operating characteristic (ROC) curves. A nomogram was constructed based on the model integrated with clinicopathologic variables.

Results: Two molecular subtypes showed distinct survival; the immune-enriched, low-purity subtype had poorer outcomes. A five-gene signature (TXNRD1, FABP5, ORMDL1, RAB5A, DBI) stratified patients into high- and low-risk groups, with AUCs of 0.90–0.94 in the training cohort and 0.58–0.85 in the validation cohort. The risk score was associated with increased ESTIMATE and immune scores, along with reduced tumor purity. The integrated nomogram achieved a C-index of 0.759 with acceptable calibration.

Conclusion: Dysregulated lipid metabolism is intricately linked to the TIME and patient prognosis in EwS. The LMRG-based risk model provides a potentially useful tool for prognostic stratification and highlights potential therapeutic avenues targeting lipid metabolism and immune modulation.

Graphical abstract
Keywords
Ewing sarcoma
Lipid metabolism
Tumor immune microenvironment
Prognostic signature
Nomogram
Funding
This research received funding from the Science and Technology Project Program of Wenzhou (Y20220928).
Conflict of interest
The authors declare they have no competing interests
References
  1. Zhang Z, Pan J, Cheng D, et al. Expression of lactate-related signatures correlates with immunosuppressive microenvironment and prognostic prediction in ewing sarcoma. Front Genet. 2022;13:965126. doi: 10.3389/fgene.2022.965126
  2. Zhang Z, Shi Y, Zhu Z, et al. Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma. Cancer Sci. 2023;114(4):1240-1255. doi: 10.1111/cas.15688
  3. Koustas E, Sarantis P, Karamouzis MV, Vielh P, Theocharis S. The Controversial Role of Autophagy in Ewing Sarcoma Pathogenesis-Current Treatment Options. Biomolecules. 2021;11(3). doi: 10.3390/biom11030355
  4. Jia F, Liu L, Weng Q, Zhang H, Zhao X. Glycolysis- Metabolism-Related Prognostic Signature for Ewing Sarcoma Patients. Mol Biotechnol. 2024;66(10):2882-2896. doi: 10.1007/s12033-023-00899-5
  5. Bierbaumer L, Katschnig AM, Radic-Sarikas B, et al. YAP/ TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis. 2021;10(1):2. doi: 10.1038/s41389-020-00294-8
  6. Tanner JM, Bensard C, Wei P, et al. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma. Mol Cancer Res. 2017;15(11):1517-1530. doi: 10.1158/1541-7786.Mcr-17-0182
  7. Jiménez JA, Apfelbaum AA, Hawkins AG, et al. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. Mol Cancer Res. 2021;19(7):1182-1195. doi: 10.1158/1541-7786.Mcr-20-0679
  8. Wang D, Ye Q, Gu H, Chen Z. The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies. Front Oncol. 2022;12:984560. doi: 10.3389/fonc.2022.984560
  9. Zeng W, Yin X, Jiang Y, Jin L, Liang W. PPARα at the crossroad of metabolic-immune regulation in cancer. FEBS J. 2022;289(24):7726-7739. doi: 10.1111/febs.16181
  10. Fu Z, Yu B, Liu M, et al. Construction of a prognostic signature in Ewing’s sarcoma: Based on metabolism-related genes. Transl Oncol. 2021;14(12):101225. doi: 10.1016/j.tranon.2021.101225
  11. Shukrun R, Baron S, Fidel V, et al. Suggested role for neutrophil extracellular trap formation in Ewing sarcoma immune microenvironment. Cancer Sci. 2024;115(1):36-47. doi: 10.1111/cas.15992
  12. He F, Xu J, Zeng F, et al. Integrative analysis of Ewing’s sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy. Cell Commun Signal. 2025;23(1):23. doi: 10.1186/s12964-024-02020-y
  13. Maan M, Peters JM, Dutta M, Patterson AD. Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun. 2018;504(3):582-589. doi: 10.1016/j.bbrc.2018.02.097
  14. Qian H, Lei T, Hu Y, Lei P. Expression of Lipid-Metabolism Genes Is Correlated With Immune Microenvironment and Predicts Prognosis in Osteosarcoma. Front Cell Dev Biol. 2021;9:673827. doi: 10.3389/fcell.2021.673827
  15. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882-883. doi: 10.1093/bioinformatics/bts034
  16. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550. doi: 10.1073/pnas.0506580102
  17. Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4-22. doi: 10.1038/s41416-019-0650-z
  18. Tang Y, Chen Z, Zuo Q, Kang Y. Regulation of CD8+ T cells by lipid metabolism in cancer progression. Cell Mol Immunol. 2024;21(11):1215-1230. doi: 10.1038/s41423-024-01224-z
  19. Chen H, Song Y, Deng C, et al. Comprehensive analysis of immune infiltration and gene expression for predicting survival in patients with sarcomas. Aging. 2020;13(2):2168-2183. doi: 10.18632/aging.202229
  20. Șenbabaoğlu Y, Michailidis G, Li JZ. Critical limitations of consensus clustering in class discovery. Sci Rep. 2014;4:6207. doi: 10.1038/srep06207
  21. Xiao B, Liu L, Li A, et al. Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma. Front Oncol. 2020;10:607622. doi: 10.3389/fonc.2020.607622
  22. Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612
  23. Zhou Y, Xu B, Wu S, Liu Y. Prognostic Immune-Related Genes of Patients With Ewing’s Sarcoma. Front Genet. 2021;12:669549. doi: 10.3389/fgene.2021.669549
  24. Fujiwara T, Fukushi J, Yamamoto S, et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol. 2011;179(3):1157-70. doi: 10.1016/j.ajpath.2011.05.034
  25. Cohnen J, Kornstädt L, Hahnefeld L, et al. Tumors Provoke Inflammation and Perineural Microlesions at Adjacent Peripheral Nerves. Cells. 2020;9(2):320. doi: 10.3390/cells9020320
  26. Shi X, Zheng Y, Jiang L, et al. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma. Nucleic Acids Res. 2020;48(20):11434-11451. doi: 10.1093/nar/gkaa901
  27. Liu R, Wang C, Tao Z, Hu G. Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment. Biomedicines. 2025;13(8):1895. doi: 10.3390/biomedicines13081895
  28. Jin R, Hao J, Yu J, Wang P, Sauter ER, Li B. Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. Cancers. 2023;15(3):657. doi: 10.3390/cancers15030657
  29. Jin HR, Wang J, Wang ZJ, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103. doi: 10.1186/s13045-023-01498-2
  30. Haight JA, Koppenhafer SL, Geary EL, Gordon DJ. Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells. Front Oncol. 2024;14:1394653. doi: 10.3389/fonc.2024.1394653
  31. Kawaguchi K, Kinameri A, Suzuki S, Senga S, Ke Y, Fujii H. The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis. Biochem J. 2016;473(4):449-461. doi: 10.1042/bj20150926
  32. Liu F, Liu W, Zhou S, et al. Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e000501. doi: 10.1136/jitc-2019-000501
  33. Wang Q, Liu W, Chen S, et al. ORMDL1 is upregulated and associated with favorable outcomes in colorectal cancer. Transl Oncol. 2021;14(10):101171. doi: 10.1016/j.tranon.2021.101171
  34. Li S, Zhao X, Fu K, et al. Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B. 2025;15(2):737-756. doi: 10.1016/j.apsb.2024.12.036
  35. Engebraaten O, Yau C, Berg K, et al. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun. 2021;12(1):6427. doi: 10.1038/s41467-021-26018-z
  36. Wu KC, Condon ND, Hill TA, Reid RC, Fairlie DP, Lim J. Ras-Related Protein Rab5a Regulates Complement C5a Receptor Trafficking, Chemotaxis, and Chemokine Secretion in Human Macrophages. J Innate Immun. 2023;15(1):468- 484. doi: 10.1159/000530012
  37. Montégut L, Liu P, Zhao L, et al. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Mol Cancer. 2024;23(1):187. doi: 10.1186/s12943-024-02098-5
  38. Li S, Motiño O, Lambertucci F, et al. Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma. Cell Rep Med. 2025;6(7):102232. doi: 10.1016/j.xcrm.2025.102232
  39. Montégut L, Martins I, Kroemer G. Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance. Autophagy. 2024;20(12):2836-2838. doi: 10.1080/15548627.2024.2411854
  40. Qu S, Xue H, Dong X, et al. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018;143(2):419-429. doi: 10.1002/ijc.31310
  41. Sun J, Yu L, Qu X, Huang T. The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy. Front Pharmacol. 2023;14:1184794. doi: 10.3389/fphar.2023.1184794
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept